Merit Medical Systems reported third-quarter sales of $416.2 million, up 8.4% from $384.2 million, and net income of $42.3 million, or $0.70 per share, versus $27.8 million, or $0.46 per share, a year earlier. Nine-month sales reached $1,217.0 million, up 8.5%, with therapeutic sales up 13.0%. The company also began commercial sales of OneMark products after acquiring View Point on April 1, 2026.
MMSI · Merit Medical Systems Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Merit Medical Systems, Inc. reported third-quarter revenue of $416.2 million, up 8.4%, with 9% organic constant-currency growth, and raised 2026 guidance. It also acquired Solo Pace on October 13, 2026 for approximately $45 million in cash.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q2 FY26 earnings call · Jul 30, 2026TL;DR. Q2 revenue beat expectations, organic growth was the strongest in three years, and full-year revenue and non-GAAP EPS guidance were raised. Headwinds include tariffs, lower operating margin excluding the tariff refund, a 2% renal therapies sales decline, and operating cash flow down 11% year-to-date.
- + Q2 total revenue beat expectations, with constant currency revenue above the high end of guidance.
- + Full-year 2026 revenue and non-GAAP EPS guidance were raised.
- + Organic growth was the strongest quarterly organic growth in three years.
- + Total OEM sales grew 15% year-over-year in Q2, with improving OEM growth trends.
- + Non-GAAP operating margin rose 142 basis points year-over-year to 22.6%.
- + Non-GAAP EPS increased 18% year-over-year.
- − Tariffs are a 2026 headwind, with the non-GAAP EPS guidance assuming a tariff impact of about $0.21 per share.
- − Operating margin excluding the tariff refund declined year-over-year.
- − Renal therapies sales declined 2% in Q2, affected by a product recall.
- − Operating cash flow fell 11% year-to-date.
- − OEM sales are inherently lumpy and may move up and down from quarter to quarter.
- − Management sees competitors active in Rhapsody, making the market a daily battle.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Foundational sales | $275.74M | FY2026 Q3 | +5.7% |
|
|
|||
| Therapeutic sales | $140.51M | FY2026 Q3 | +14.0% |
|
|
|||
| Aggregate amortization expense for developed technology and other intangible assets | $21.2M | Three Months Ended June 30, 2026 filing | — |
| Capital Expenditures-Property and Equipment | $17.3M | Q2 2026 | — |
| Constant Currency Revenue non-GAAP | 789.8M | Six Months Ended June 30, 2026 | — |
| Constant Currency Revenue, Organic non-GAAP | 774.45M | Six Months Ended June 30, 2026 | — |
| Domestic sales | $252.1M | three months ended June 30, 2026 filing | — |
| Effective tax rate | 24.4% | Three Months Ended June 30, 2026 filing | — |
| employees worldwide | 7,500 | as of release date | — |
| Free cash flow non-GAAP | $76.6M | Six months ended June 30, 2026 | — |
| Gross profit percentage | 51.4% | three months ended June 30, 2026 filing | — |
| International sales | $166.8M | three months ended June 30, 2026 filing | — |
| Non-GAAP EPS non-GAAP | $2.13 | Six Months Ended June 30, 2026 | +13.9% |
|
|
|||
| Non-GAAP Gross Margin non-GAAP | 54.6% | Six Months Ended June 30, 2026 | — |
| Non-GAAP net income non-GAAP | 127.94M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Operating Income non-GAAP | 169.89M | Six Months Ended June 30, 2026 | — |
| Non-GAAP Operating Margin non-GAAP | 21.2% | Six Months Ended June 30, 2026 | +5.0% |
| Operating Cash Flow | $69.3M | Q2 2026 | — |
| Selling, general and administrative expense as a percentage of sales | 30.9% | three months ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MMSI
this stock
Merit Medical Systems Inc
|
$5.15B | -2.5% | +11.8% | 32.2 | 6.7% |
|
ISRG
Intuitive Surgical Inc
|
$145.92B | -25.7% | +20.5% | 51.0 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$58.86B | — | +8.2% | 95.6 | 3.0% |
|
MDLN
Medline Inc.
|
$51.51B | -6.8% | +11.5% | — | 2.9% |
|
ALC
Alcon Inc
|
$36.15B | -4.5% | +10.5% | — | 3.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Oct 29, 2026
- This year
- 21
Merit Medical Systems reported third-quarter sales of $416.2 million, up 8.4% from $384.2 million, and net income of $42.3 million, or $0.70 per share, versus $27.8 million, or $0.46 per share, a year earlier. Nine-month sales reached $1,217.0 million, up 8.5%, with therapeutic sales up 13.0%. The company also began commercial sales of OneMark products after acquiring View Point on April 1, 2026.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MMSI | -2.4% | -6.0% | +36.3% | -0.4% | -2.5% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +1.5% | -0.4% | +39.7% | +3.0% | -9.6% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.